T. Rowe Price Investment Management
CLB icon

T. Rowe Price Investment Management’s Core Laboratories CLB Stock Holding History

T. Rowe Price Investment Management’s Portfolio CLB Stock Details CLB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.65M Sell
485,032
-618,863
-56% -$8.83M ﹤0.01% 642
2026
Q1 		$18.5M Buy
1,103,895
+61,687
+6% +$1.1M 0.01% 475
2025
Q4 		$16.7M Buy
1,042,208
+134,050
+15% +$2M 0.01% 517
2025
Q3 		$11.2M Buy
908,158
+33,117
+4% +$388K 0.01% 550
2025
Q2 		$10.1M Sell
875,041
-223,587
-20% -$2.65M 0.01% 557
2025
Q1 		$16.5M Sell
1,098,628
-60,074
-5% -$1.01M 0.01% 530
2024
Q4 		$20.1M Buy
1,158,702
+46,941
+4% +$906K 0.01% 512
2024
Q3 		$20.6M Buy
1,111,761
+184,264
+20% +$3.7M 0.01% 511
2024
Q2 		$18.8M Buy
+927,497
New +$16.4M 0.01% 505

Other funds holding CLB

AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CAMG
CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

T. Rowe Price Investment Management's CLB Position: Q2 2026 in Review

T. Rowe Price Investment Management reduced its Core Laboratories (CLB) stake by 56% in Q2 2026, selling an estimated $8.83M and leaving 485,032 shares worth $5.65M. The position accounts for ﹤0.01% of the portfolio, ranked #642.

T. Rowe Price Investment Management first reported a position in CLB in Q2 2024 and has held it in 9 quarters since. The position peaked at $20.6M in Q3 2024. 186 funds tracked by Wall St. Rank hold CLB as of Q2 2026.

  • T. Rowe Price Investment Management held 485,032 shares of Core Laboratories worth $5.65M as of Q2 2026.
  • T. Rowe Price Investment Management sold 618,863 Core Laboratories shares in Q2 2026, an estimated $8.83M.
  • Core Laboratories made up ﹤0.01% of T. Rowe Price Investment Management's portfolio in Q2 2026, its #642 holding.
  • T. Rowe Price Investment Management first reported a position in Core Laboratories in Q2 2024 and has held it in 9 quarters since.
  • T. Rowe Price Investment Management's Core Laboratories position peaked at $20.6M in Q3 2024.
  • 186 funds tracked by Wall St. Rank held Core Laboratories as of Q2 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.